New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 27, 2014
16:27 EDTAMED, MNKD, NKE, DG, FINL, MTW, DDOn The Fly: Closing Wrap
Stocks on Wall Street were higher after a late day rise allowed all of the major averages to end the week on a high note. The averages began the session in negative territory but soon turned mixed. The Nasdaq was able to hold its head above water for most of the session while the Dow struggled for most of the day under the weight of DuPont (DD) shares, which were down more than 3% after the company lowered its guidance. ECONOMIC EVENTS: In the U.S., the final University of Michigan consumer sentiment index for June rose to 82.5, which beat the consensus expectation for a reading of 81.9. COMPANY NEWS: Shares of athletic apparel and footwear giant Nike (NKE) and sports shoe retailer Finish Line (FINL) climbed after both companies reported better than expected quarterly sales and profits. Dow member Nike rose 82c, or 1.07%, to $77.68, while Finish Line advanced 41c, or 1.41%, to $29.56... Another member of the Dow Jones Industrial Average, DuPont, moved in the opposite direction, falling $2.26, or 3.34%, to $65.44 after the industrial conglomerate cut its earnings outlook for its second quarter and its current fiscal year. MAJOR MOVERS: Among the notable gainers was Amedisys (AMED), which rose $4.01, or 29.81%, to $17.46 and was upgraded at CRT Capital after the company gave Q2 guidance. Also higher was Manitowoc (MTW), which gained $3.22, or 10.84%, to $32.93 and was upgraded to Hold at Jefferies after activist Relational Investors took an 8.5% stake in the company and urged for a spin-off of its food business. Among the noteworthy losers was discount retailer Dollar General (DG), which fell $4.49, or 7.28%, to $57.19 after Chief Executive Officer Rick Dreiling announced plans to retire. Also lower were shares of MannKind (MNKD), which dropped 58c, or 5.48%, to $10.00 after the FDA approved its Afrezza inhalation powder to treat diabetes but required the drug to have a Boxed Warning and required the company to conduct several post-marketing studies on the drug. INDEXES: The Dow was up 5.71, or 0.03%, to 16,851.84, the Nasdaq was up 18.88, or 0.43%, to 4,397.93, and the S&P 500 was up 3.74, or 0.19%, to 1,960.96.
News For NKE;DD;FINL;MNKD;MTW;DG;AMED From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
May 14, 2015
06:58 EDTDDDuPont pullback a buying opportunity, says Deutsche Bank
Subscribe for More Information
06:28 EDTDDDuPont upgraded to Neutral from Underperform at BofA/Merrill
Subscribe for More Information
May 13, 2015
16:23 EDTDDOn The Fly: Top stock stories for Wednesday
Subscribe for More Information
16:06 EDTDDOptions Update; May 13, 2015
iPath S&P 500 VIX Short-Term Futures down 38c to 20.67. Option volume leaders: AAPL CSCO NTI FB CSX BABA EIX BAC DD WMB TSLA JCP QCOM DAL
12:39 EDTDDOn The Fly: Top stock stories at midday
Subscribe for More Information
10:04 EDTDDDuPont drops after winning proxy fight with Trian Partners
Subscribe for More Information
09:56 EDTDDEquity options with increasing volume
Subscribe for More Information
08:51 EDTDDTrian says 'appears Trian nominees not elected to DuPont board'
Trian Fund Management, L.P., one of the largest stockholders of E. I. du Pont de Nemours and Company, which beneficially owns approximately 24.6 million DuPont shares, said it appears that the Trian nominees were not elected to the DuPont Board at todayís Annual Meeting of Stockholders. Trian issued the following statement: "Trianís involvement in DuPont over the past two years has created substantial value for all stockholders. We are proud of the quality of our analysis and the role we have played as a positive change agent at DuPont. Since we first invested in mid-2013, DuPont has upgraded its Board of Directors, authorized a $5 billion share buyback, begun a long-overdue cost cutting initiative, improved the design of its executive compensation program, and announced the separation of Chemours with a $4 billion return of capital. We donít believe these actions would have happened without our involvement. The vote was close. We greatly appreciate the support we received from the vast majority of institutional stockholders and mutual funds as well as the leading proxy advisory firms, who all recognize the need for change at DuPont. DuPontís Board and management team have staked their reputations on executing the Companyís current strategy. Our efforts have created appropriate pressure to prove this strategy can actually deliver high quality and consistent earnings growth. Regardless of the voting results, we believe that going forward, DuPont stockholders will be less tolerant of continued missed earnings guidance, extraordinary charges, value-destructive acquisitions and divestitures, executive compensation that is not aligned with performance, and operating metrics such as revenue growth and margins that fail to meet DuPontís own targets. We will continue to closely monitor DuPontís performance.Ē
08:31 EDTDDDuPont seen winning close proxy fight, CNBC's Faber reports
Subscribe for More Information
08:29 EDTDDDuPont seen winning proxy fight, CNBC's Faber reports
Subscribe for More Information
May 12, 2015
07:35 EDTAMEDBofA/Merrill to hold a conference
Subscribe for More Information
05:58 EDTMNKDStocks with implied volatility movement; MNKD BBRY
Subscribe for More Information
05:26 EDTDDDuPont issues statement regarding Trian's statements
Subscribe for More Information
May 11, 2015
12:51 EDTMNKDOn The Fly: Top stock stories at midday
Subscribe for More Information
12:28 EDTDDPeltz says 'we don't even think of not winning' DuPont proxy contest
Subscribe for More Information
12:24 EDTDDPeltz says chances for last minute deal with DuPont 'dim'
Nelson Peltz says he wants to be collaborative with DuPont, adding that he is restricted in his comments about DuPont due to legal reasons as his proxy fight with the company continues. Peltz, however, said the prospects for a last minute settlement with DuPont are "very dim" and that his last talks with DuPont were weeks ago. Peltz said he and Trian are committed to maintaining R&D levels at DuPont. Nelson Peltz of Trian Fund Management is speaking on CNBC.
11:32 EDTDDDuPont indicates support from CalPERS, others for board nominees
Subscribe for More Information
09:59 EDTMNKDOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:21 EDTMNKDOn The Fly: Pre-market Movers
Subscribe for More Information
06:43 EDTMNKDMannKind downgraded to Underweight from Neutral at JPMorgan
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use